Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) regarding the potential sale of an experimental drug for a debilitating stomach disease.
The drug at the center of the talks is RVT-3101 for ulcerative colitis and Crohn’s disease.
The deal, which may exceed $7 billion in value, could be announced in the near future, according to sources familiar with the matter. However, the negotiations are still ongoing Wall Street Journal reported, and there is a possibility that the talks could collapse or another buyer could emerge.
Since its establishment in 2014 by Ramaswamy, Roivant has primarily focused on acquiring stalled drugs and establishing subsidiaries to develop …
